论文部分内容阅读
将68例EH合并T2DM患者随机分为治疗组给予罗格列酮4mg.d-1,二甲双胍2000mg.d-1,苯那普利(洛汀新)10~20mg.d-1,阿司匹林100mg.d-1,po;对照组给予二甲双胍2000mg.d-1,苯那普利10~20mg.d-1,阿司匹林100mg.d-1,po。疗程12周。结果SBP、2hPG、HbA1c和FINS,FBG、TG和LDL-C,两组均有明显下降(P<0.05),两组间相比有明显差异(P<0.05);DBP两组均有下降,心率和HDL-C,两组均有升高,但两组间无明显差异(P>0.05);BMI和TC,两组均有所改善,但无明显差异(P>0.05)。结论罗格列酮治疗EH合并T2MD是一个安全有效的药物。
Sixty-eight EH patients with T2DM were randomly divided into treatment group with rosiglitazone 4mg.d-1, metformin 2000mg.d-1, benazepril (Lotensin) 10 ~ 20mg.d-1 and aspirin 100mg. d-1, po; the control group was given metformin 2000mg.d-1, benazepril 10 ~ 20mg.d-1, aspirin 100mg.d-1, po. Treatment for 12 weeks. Results The levels of SBP, 2hPG, HbA1c, FINS, FBG, TG and LDL-C in both groups were significantly decreased (P <0.05), and there was significant difference between the two groups (P < Heart rate and HDL-C increased in both groups, but there was no significant difference between the two groups (P> 0.05). BMI and TC were improved in both groups, but there was no significant difference (P> 0.05). Conclusions Rosiglitazone is a safe and effective drug for EH with T2MD.